Caroline Robert

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. ncbi request reprint Cutaneous side-effects of kinase inhibitors and blocking antibodies
    Caroline Robert
    Department of Medical Oncology, Dermatology Unit, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94801Villejuif Cedex, France
    Lancet Oncol 6:491-500. 2005
  2. ncbi request reprint Tyrosine kinase inhibition and grey hair
    Caroline Robert
    Lancet 361:1056. 2003
  3. ncbi request reprint Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma
    Bruce Elliott
    Royal Surrey County Hospital Guildford, Guildford, United Kingdom
    Clin Cancer Res 13:3825-30. 2007
  4. ncbi request reprint [Cutaneous side effects of antiangiogenic agents]
    Caroline Robert
    Service de Dermatologie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94800 Villejuif
    Bull Cancer 94:S260-4. 2007
  5. doi request reprint Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor
    Julien Autier
    Dermatology Unit, Gustave Roussy Institute, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Arch Dermatol 144:886-92. 2008
  6. doi request reprint [Management of side effects of targeted therapies in renal cancer: cutaneous side effects]
    Caroline Robert
    Institut Gustave Roussy, Service de Dermatologie, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France Electronic address
    Bull Cancer 98:S35-46. 2011
  7. doi request reprint Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
    Caroline Robert
    Institute Gustave Roussy, Paris, France
    Lancet Oncol 14:733-40. 2013
  8. doi request reprint Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control
    Caroline Robert
    Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 19:2232-9. 2013
  9. doi request reprint Advances in the management of cutaneous toxicities of targeted therapies
    Caroline Robert
    Institute Gustave Roussy, Villejuif, France
    Semin Oncol 39:227-40. 2012
  10. doi request reprint What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?
    Caroline Robert
    Institute Gustave Roussy, 94805 Villejuif Cedex, France
    Oncologist 14:848-61. 2009

Detail Information

Publications57

  1. ncbi request reprint Cutaneous side-effects of kinase inhibitors and blocking antibodies
    Caroline Robert
    Department of Medical Oncology, Dermatology Unit, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94801Villejuif Cedex, France
    Lancet Oncol 6:491-500. 2005
    ..Elucidation of this connection could lead to the identification of crucial predictive factors for tumour response...
  2. ncbi request reprint Tyrosine kinase inhibition and grey hair
    Caroline Robert
    Lancet 361:1056. 2003
  3. ncbi request reprint Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma
    Bruce Elliott
    Royal Surrey County Hospital Guildford, Guildford, United Kingdom
    Clin Cancer Res 13:3825-30. 2007
    ..The aim of this study was to investigate the prognostic importance of the maximal density of mature DCs in SLNs...
  4. ncbi request reprint [Cutaneous side effects of antiangiogenic agents]
    Caroline Robert
    Service de Dermatologie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94800 Villejuif
    Bull Cancer 94:S260-4. 2007
    ..It will help us understanding better skin pathophysiology, but, most of all, it will lead to more efficient symptomatic treatment for our patients...
  5. doi request reprint Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor
    Julien Autier
    Dermatology Unit, Gustave Roussy Institute, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Arch Dermatol 144:886-92. 2008
    ..To provide an accurate description and to evaluate the incidence and severity of cutaneous reactions induced by sorafenib tosylate, a new oral multikinase inhibitor...
  6. doi request reprint [Management of side effects of targeted therapies in renal cancer: cutaneous side effects]
    Caroline Robert
    Institut Gustave Roussy, Service de Dermatologie, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France Electronic address
    Bull Cancer 98:S35-46. 2011
    ..This guideline describes the incidence, clinical presentation and treatment of dermatologic side effects that develop with the use of targeted therapies (sunitinib, sorafenib, pazopanib, bevacizumab, everolimus, temsirolimus). ..
  7. doi request reprint Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
    Caroline Robert
    Institute Gustave Roussy, Paris, France
    Lancet Oncol 14:733-40. 2013
    ..This study was designed to look for a signal of improved efficacy by comparing the combination of selumetinib and dacarbazine with dacarbazine alone...
  8. doi request reprint Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control
    Caroline Robert
    Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 19:2232-9. 2013
    ..Here, outcomes for these patients concerning baseline characteristics, best overall response, and disease control rate are assessed and considered with respect to the overall study population...
  9. doi request reprint Advances in the management of cutaneous toxicities of targeted therapies
    Caroline Robert
    Institute Gustave Roussy, Villejuif, France
    Semin Oncol 39:227-40. 2012
    ..We will review the skin side effects of EGFR, VEGFR, KIT, platelet-derived growth factor receptor (PDGFR), and BCR-ABL inhibitors, as well as mTOR inhibitors...
  10. doi request reprint What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?
    Caroline Robert
    Institute Gustave Roussy, 94805 Villejuif Cedex, France
    Oncologist 14:848-61. 2009
    ..However, the true advantage of these new drugs may depend largely on the characterization of predictive biomarkers of activity and subsequent targeting of responsive patients...
  11. doi request reprint [What is new in oncodermatology?]
    C Robert
    Service de Dermatologie, Institut Gustave Roussy, Villejuif, France
    Ann Dermatol Venereol 135:S354-9. 2008
    ..Besides melanoma, the scoop of the year was the discovery of a defective oncogenic polyomavirus which is very likely to be responsible for Merkel cell carcinoma...
  12. doi request reprint [Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma]
    Caroline Robert
    Institut Gustave Roussy, Villejuif, France
    Med Sci (Paris) 27:850-8. 2011
    ..The challenges are now to identify biomarkers able to predict ipilimumab benefit and to know how to use ipilimumab in combination with new targeted therapies of melanoma in order to optimize the treatment efficacy...
  13. doi request reprint Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1
    Jean Philippe Arnault
    Department of Medical Oncology and Pathology, Institute Gustave Roussy, Villejuif, France
    Clin Cancer Res 18:263-72. 2012
    ..We carried out a clinical, pathologic, and molecular study of skin lesions occurring in patients receiving sorafenib...
  14. pmc Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha
    Sophie Viaud
    Institut National de la Sante et de la Recherche Medicale, Unité 805, Villejuif, France
    PLoS ONE 4:e4942. 2009
    ..Altogether, these data provide a mechanistic explanation on how Dex may stimulate non MHC restricted-anti-tumor effectors and induce tumor regression in vivo...
  15. doi request reprint Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients
    Cedric Menard
    Institut National de la Sante et de la Recherche Medicale INSERM, Unit U805 Tumor immunology and immunotherapy, Villejuif, France
    Cancer Res 69:3563-9. 2009
    ..The NK cell IFN-gamma production after 2 months of treatment could be considered an independent predictor of long term survival in advanced GISTs treated with IM...
  16. doi request reprint Dermatologic symptoms associated with the multikinase inhibitor sorafenib
    Caroline Robert
    Department of Medicine, Dermatology Unit, Institut Gustave Roussy, Villejuif, France
    J Am Acad Dermatol 60:299-305. 2009
    ..The multikinase inhibitor sorafenib (Nexavar) is associated with a relatively high incidence of dermatologic symptoms...
  17. ncbi request reprint Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 13:1801-9. 2007
    ..To determine the safety, maximum tolerated dose, pharmacokinetics, and efficacy, and to evaluate biomarkers, of the multikinase inhibitor sorafenib plus IFN alpha-2a in advanced renal cell carcinoma (RCC) or melanoma...
  18. doi request reprint Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
    Cedric Menard
    Center of Clinical Investigations, CBT507, Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 14:5242-9. 2008
    ..However, mechanisms of action and surrogate immunologic markers of efficacy have not been reported thus far...
  19. doi request reprint ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway
    Ahmed Hamai
    Institut National de la Sante et de la Recherche Medicale, U753, Laboratoire d Immunologie des Tumeurs Humaines Interaction effecteurs cytotoxiques système tumoral, Institut Gustave Roussy PR1 and IFR 54, Villejuif, France
    Cancer Res 68:9854-64. 2008
    ..The present study shows that a shift in ICAM-1 expression, which was associated with an activation of the PI3K/AKT pathway, can be used by metastatic melanoma cells to escape CTL-mediated killing...
  20. doi request reprint Anti-CTLA-4 antibody adjuvant therapy in melanoma
    Alexander M M Eggermont
    Institut d Oncologie Gustave Roussy, Villejuif, France
    Semin Oncol 37:455-9. 2010
    ..The EORTC 18071 trial will reach full accrual in 2011 and thus results are expected in 2013 or 2014...
  21. doi request reprint Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    Caroline Robert
    Institute Gustave, Roussy, Villejuif, France
    N Engl J Med 364:2517-26. 2011
    ..We conducted a phase 3 study of ipilimumab (10 mg per kilogram) plus dacarbazine in patients with previously untreated metastatic melanoma...
  22. doi request reprint Vemurafenib and radiosensitization
    Lise Boussemart
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    JAMA Dermatol 149:855-7. 2013
    ..Cutaneous adverse effects are preeminent with UV-A-dependent phototoxicity, hyperkeratotic folliculitis, hand-foot skin reaction, hair changes, verrucous papillomas, keratoacanthomas, and squamous cell carcinomas...
  23. doi request reprint Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991
    Alexander M M Eggermont
    Institut de Cancerologie Gustave Roussy, Villejuif, France
    Eur J Cancer 48:218-25. 2012
    ..Adjuvant interferon has modest activity in melanoma patients at high risk for relapse. Patient selection is important; stage and ulceration of the primary tumour are key prognostic factors...
  24. doi request reprint Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas
    Caroline Kannengiesser
    Service de Génétique and CNRS FRE 2939, Institut Gustave Roussy, Villejuif, France
    Mol Oncol 1:425-30. 2008
    ....
  25. doi request reprint Gap junction communication between autologous endothelial and tumor cells induce cross-recognition and elimination by specific CTL
    Houssem Benlalam
    Institut National de la Santé et de la Recherche Médicale Unite 753, Institut Fédératif de Recherche 54, Villejuif, France
    J Immunol 182:2654-64. 2009
    ..Our results indicate that gap junctions facilitate an effective CTL-mediated destruction of endothelial cells from the tumor microenvironment that may contribute to the control of tumor progression...
  26. doi request reprint Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
    Michele Maio
    Michele Maio, University Hospital of Siena, Siena Vanna Chiarion Sileni, Veneto Oncology Institute Istituto Di Ricovero e Cura a Carattere Scientifico, Padova Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy Jean Jacques Grob, Aix Marseille University, Assistance Publique Hopitaux de Marseille, Hopital Timone, Marseille Luc Thomas, Lyon 1 University, Centre Hospitalier Lyon Sud, Pierre Bénite Caroline Robert, Institute Gustave Roussy, Villejuif, France Steinar Aamdal, Oslo University Hospital and Radium Hospital, Oslo, Norway Igor Bondarenko, Dnepropetrovsk State Medical Academy, Dnepropetrovsk, Ukraine Claus Garbe, University Medical Center, Tubingen, Germany Tai Tsang Chen and Marina Tschaika, Bristol Myers Squibb, Wallingford, CT and Jedd D Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 33:1191-6. 2015
    ..To demonstrate a long-term survival benefit with ipilimumab, we evaluated the 5-year survival rates of patients treated in a randomized, controlled phase III trial...
  27. doi request reprint CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients
    Patrick A Ott
    Authors Affiliations Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts and Institut Gustave Roussy, Villejuif Paris Sud, Paris, France
    Clin Cancer Res 19:5300-9. 2013
    ..Clin Cancer Res; 19(19); 5300-9. ©2013 AACR. ..
  28. ncbi request reprint Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
    Sandrine Faivre
    Department of Medicine, Gustave Roussy Institute, Villejuif, France
    J Clin Oncol 24:25-35. 2006
    ..To establish the safety, pharmacokinetics, and recommended dose of sunitinib, a novel oral multitargeting tyrosine kinase inhibitor with antiangiogenic and antitumor properties, in patients with advanced malignancies...
  29. doi request reprint Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?
    Alexander M M Eggermont
    Institut de Cancerologie Gustave Roussy, Villejuif, Paris, France
    Curr Opin Oncol 24:137-40. 2012
    ..Patients with an ulcerated melanoma do much worse than patients with a nonulcerated melanoma with the same breslow thickness. Ulceration may indicate a separate biologic entity...
  30. doi request reprint Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors
    Matthew Holderfield
    Authors Affiliations Novartis Institutes for BioMedical Research, Emeryville UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California Dermatology Unit and INSERM U 981 Department of Medical Biology and Pathology Laboratory and Biobank INSERM U 981, Institut Gustave Roussy, Villejuif Paris Sud and Unité de Génétique, Papillomavirus et Cancer Humain, Institut Pasteur, Paris, France
    Cancer Res 74:2238-45. 2014
    ..Our results argue that HPV cooperates with vemurafenib to promote tumorigenesis, in either the presence or absence of RAS mutations...
  31. doi request reprint Regulation of gap junctions in melanoma and their impact on Melan-A/MART-1-specific CD8⁺ T lymphocyte emergence
    Houssem Benlalam
    Institut National de la Santé et de la Recherche Médicale INSERM U753, Institut Fédératif de Recherche 54 IFR54, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France
    J Mol Med (Berl) 91:1207-20. 2013
    ..These findings indicate that Cx43 does not affect lytic function of differentiated CTL, but reveal a major role for GJs in the regulation of antigen CD8(+)-naïve T lymphocyte activation...
  32. doi request reprint [Detection of residual microscopic disease in melanoma: interest of the sentinel lymph node procedure?]
    Christine Mateus
    Universite Paris Sud, Service de Dermatologie, Gustave Roussy, 114, rue Edouard Vaillant, 94805 Villejuif Cedex, France
    Bull Cancer 101:354-7. 2014
    ..Other trials probably more attractive (anti-CTLA4, BRAF and MEK inhibitors), with molecules recently approved in metastatic phase are also ongoing. ..
  33. doi request reprint Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses
    Stephan Roux
    INSERM U805, Villejuif, France
    Cancer Immunol Immunother 57:1291-300. 2008
    ..We addressed whether tumor-associated antigens released after ECT could induce an efficient systemic immunity when associated with an appropriate immunoadjuvant...
  34. doi request reprint Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib
    Guillaume Bollée
    APHP, Service de Néphrologie Adulte, Hopital Necker, Paris, France
    Nephrol Dial Transplant 24:682-5. 2009
    ..The patient was given irbesartan, and sunitinib was continued for 3 months after diagnosis. Over this period, blood pressure and renal function remained stable and proteinuria became undetectable...
  35. doi request reprint New drugs in melanoma: it's a whole new world
    Alexander M M Eggermont
    Institut de Cancerologie Gustave Roussy, Villejuif, Paris Sud, France
    Eur J Cancer 47:2150-7. 2011
    ..Adjuvant trials with BRAF and MEK inhibitors are in the planning phase. Never was there a more exciting period in the world of melanoma treatment...
  36. doi request reprint Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples
    Vladimir Lazar
    Department of Functional Genomics, Institut Gustave Roussy, University Paris Sud, Villejuif, France
    Invest New Drugs 32:312-22. 2014
    ..The objective of this study was also to validate functional parameters of DCE-US as surrogate markers to predict earlier response...
  37. doi request reprint Severe meningo-radiculo-neuritis associated with ipilimumab
    Flavie Bompaire
    Service de Neurologie, Hôpital d Instruction des Armées du Val de Grâce, service de santé des armées, Paris, France
    Invest New Drugs 30:2407-10. 2012
    ..In phase III trials, ipilimumab was shown to be the first agent to improve survival in advanced melanoma patients, regardless of previous treatment. We report a case of severe neurologic disease after ipilimumab treatment...
  38. doi request reprint [Major therapeutic advances in the treatment of metastatic melanoma]
    Christine Mateus
    Institut Gustave Roussy, Service de Dermatologie, 39, rue Camille Desmoulins, 94805 Villejuif, France
    Bull Cancer 99:619-25. 2012
    ..New combination therapies and additional targeted and immunotherapy agents are exciting perspectives that make us more optimistic for the future of metastatic melanoma treatment...
  39. ncbi request reprint [Epithelial and melanic skin tumours]
    Christine Mateus
    Service de Dermatologie, Institut Gustave Roussy, Villejuif Cedex
    Rev Prat 57:2067-79. 2007
  40. doi request reprint Kidney injuries related to ipilimumab
    Hassane Izzedine
    Department of Nephrology, Pitie Salpetriere, 47 80 Boulevard de l Hôpital, 75013, Paris, France
    Invest New Drugs 32:769-73. 2014
    ..Autoimmune symptoms have to be carefully checked for patients treated with CTLA-4 inhibitors. In order to reduce the risk of sequelae, early recognition of irAEs and treatment initiation are crucial. ..
  41. doi request reprint Targeted therapy-induced radiation recall
    Antonin Levy
    Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 49:1662-8. 2013
    ..A diverse range of chemotherapies has been associated with RR but no case series with targeted therapies (TT) has been reported...
  42. doi request reprint [Immunotherapies and melanoma]
    Emilie Routier
    Gustave Roussy, Service de Dermatologie, 114, rue Edouard Vaillant, 94805 Villejuif Cedex, France Electronic address
    Bull Cancer 101:S13-24. 2014
    ..The challenge for the next years will be to optimize these new strategies, by possibly using these new drugs sequentially or in combination for a higher clinical benefit for our patients. ..
  43. doi request reprint Immunotherapies and melanoma
    Emilie Routier
    Gustave Roussy, Service de Dermatologie, 114, rue Edouard Vaillant, 94805 Villejuif Cedex, France
    Bull Cancer 101:13-24. 2014
    ..The challenge for the next years will be to optimize these new strategies, by possibly using these new drugs sequentially or in combination for a higher clinical benefit for our patients. ..
  44. doi request reprint Update on the role of ipilimumab in melanoma and first data on new combination therapies
    Michele Maio
    Medical Oncology and Immunotherapy, Azienda Ospedaliera Universitaria Senese, Istituto Toscano Tumori, Siena, Italy
    Curr Opin Oncol 25:166-72. 2013
    ..This article provides an update on the therapeutic role of the monoclonal antibody ipilimumab in melanoma. Recent therapeutic combinations, as well as directions for further investigations, will also be discussed...
  45. ncbi request reprint Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma
    Mojgan Movassagh
    Immunology Institut National de la Santé et de la Recherche Médicale ERM0208 and Immunotherapy Unit, Department of Pathology, Dermatology Unit, Institut Gustave Roussy, 94805 Villejuif Cedex, France
    Cancer Res 64:2192-8. 2004
    ....
  46. pmc Imaging of melanoma: usefulness of ultrasonography before and after contrast injection for diagnosis and early evaluation of treatment
    Linda Chami
    Imaging Department Institut Gustave Roussy, Villejuif, France
    Clin Cosmet Investig Dermatol 4:1-6. 2011
    ....
  47. doi request reprint Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
    Dalil Hannani
    1 Gustave Roussy Cancer Campus, Villejuif, France 2 INSERM U1015, Villejuif, France 3 Université Paris Sud XI, Faculte de Medecine, Le Kremlin Bicetre, France
    Cell Res 25:208-24. 2015
    ..Importantly, our study provides the first immunologically relevant biomarker, namely elevated serum sCD25, that predicts resistance to CTLA-4 blockade in patients with melanoma. ..
  48. doi request reprint Side effects and toxicities of targeted therapies in stage IV melanoma
    Paolo A Ascierto
    1Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori Fondazione G Pascale, Naples, Italy 2Odense University Hospital, Odense, Denmark 3Newcastle University, Newcastle, Australia 4Instituto de Oncologia Angel Rolfo, Buenos Aires, Argentina 5Institut Gustave Roussy, Villejuif, France 6University of Kiel, Kiel, Germany 7Hospital La Paz, Madrid, Spain and 8Institut Gustave Roussy, Villejuif, France
    Am J Ther 22:44-53. 2015
    ..With new treatment opportunities come increased chance of toxic reactions. The key to successful melanoma treatment in the future is likely to be novel combinations of new therapeutic agents. ..
  49. doi request reprint [Axitinib in metastatic renal carcinomas: update of knowledge about side effects]
    Laurence Albiges
    Institut Gustave Roussy, Departement d Oncologie Medicale, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Bull Cancer 101:976-88. 2014
    ..The objective of this article is to summarize the knowledge as for the side effects related to axitinib in terms of incidence, etiology and symptoms for the effects requiring a specific management...
  50. pmc Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects
    Christophe Borg
    Department of Clinical Biology, Equipe de Recherche Mixte 0208, INSERM, Institut Gustave Roussy, Villejuif, France
    J Clin Invest 114:379-88. 2004
    ..These data point to a novel mode of antitumor action for Gleevec...
  51. ncbi request reprint RAF inhibition and induction of cutaneous squamous cell carcinoma
    Caroline Robert
    Department of Medicine, Gustave Roussy Institute, Villejuif, France
    Curr Opin Oncol 23:177-82. 2011
    ..The purpose of this review is to discuss the mechanisms as well as the management and implications of this unexpected side-effect...
  52. ncbi request reprint [Management of recurrent soft tissue sarcoma of the retroperitoneum]
    Sylvie Bonvalot
    Departement de Chirurgie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif
    Bull Cancer 91:845-52. 2004
    ..Adequate management at the time of primary presentation is likely to afford the best chance for long-term survival...
  53. doi request reprint Thyroid adenomas and carcinomas following radiotherapy for a hemangioma during infancy
    Nadia Haddy
    INSERM, U605, Villejuif, France
    Radiother Oncol 93:377-82. 2009
    ..This paper presents the incidence of differentiated thyroid adenomas and carcinomas after radiotherapy in this cohort...
  54. ncbi request reprint Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?
    Caroline Robert
    Ann Intern Med 143:313-4. 2005
  55. ncbi request reprint Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients
    Nadege Bercovici
    IDM, Hopital Europeen Georges Pompidou, Unité d Immunologie Biologique, EA 4054 Université Paris, France
    J Immunother 31:101-12. 2008
    ..The differential expression of perforin and IFN-gamma by antitumor and antiviral CD8+ T cells supports that the sole use of IFN-gamma production to monitor T cells overlooks functional T-cell subpopulations triggered by vaccines...
  56. ncbi request reprint Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases
    Florent Grange
    Department of Dermatology, Hopital Robert Debre, avenue du Général Koenig, Reims 51100, France
    Arch Dermatol 143:1144-50. 2007
    ....
  57. pmc CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner
    Francois Ghiringhelli
    ERM 0208, Institut National de la Sante et de la Recherche Medicale INSERM, University of Paris XI, France
    J Exp Med 202:1075-85. 2005
    ..Human NK cell-mediated tumor recognition could also be restored by depletion of T reg cells from tumor-infiltrating lymphocytes. These findings support a role for T reg cells in blunting the NK cell arm of the innate immune system...